Alumis Inc. $ALMS Holdings Increased by Profund Advisors LLC

Profund Advisors LLC boosted its stake in shares of Alumis Inc. (NASDAQ:ALMS) by 1,010.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 158,249 shares of the company’s stock after acquiring an additional 143,998 shares during the quarter. Profund Advisors LLC’s holdings in Alumis were worth $1,169,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. grew its holdings in shares of Alumis by 20.2% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 23,617 shares of the company’s stock worth $172,000 after purchasing an additional 3,973 shares during the last quarter. Integrated Wealth Concepts LLC bought a new position in Alumis in the 2nd quarter valued at $33,000. Corient Private Wealth LP lifted its position in Alumis by 88.1% during the 2nd quarter. Corient Private Wealth LP now owns 35,144 shares of the company’s stock valued at $989,000 after purchasing an additional 16,458 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in Alumis in the second quarter valued at approximately $422,000. Finally, Moore Capital Management LP boosted its position in shares of Alumis by 230.7% in the 2nd quarter. Moore Capital Management LP now owns 136,803 shares of the company’s stock worth $3,850,000 after purchasing an additional 95,433 shares during the last quarter.

Wall Street Analysts Forecast Growth

ALMS has been the topic of several recent analyst reports. Citigroup reissued an “overweight” rating on shares of Alumis in a research note on Tuesday, September 1st. Cantor Fitzgerald restated an “overweight” rating on shares of Alumis in a report on Wednesday, September 16th. HC Wainwright restated a “buy” rating on shares of Alumis in a research note on Monday, October 5th. Wells Fargo & Company reduced their price objective on shares of Alumis from $51.00 to $25.00 and set an “overweight” rating for the company in a research note on Wednesday, September 2nd. Finally, Oppenheimer decreased their target price on shares of Alumis from $55.00 to $37.00 and set an “outperform” rating for the company in a research note on Wednesday, September 2nd. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $33.27.

Alumis Stock Performance

ALMS stock opened at $6.50 on Wednesday. Alumis Inc. has a 52 week low of $4.40 and a 52 week high of $31.35. The company’s 50-day simple moving average is $9.17 and its 200 day simple moving average is $21.23.

Alumis (NASDAQ:ALMS) last announced its earnings results on Thursday, August 13th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.34). The business had revenue of $1.66 million for the quarter, compared to analyst estimates of $3.65 million. Alumis had a negative return on equity of 93.15% and a negative net margin of 5,933.46%. As a group, analysts anticipate that Alumis Inc. will post -2.95 earnings per share for the current year.

Insider Buying and Selling at Alumis

In other news, Director Srinivas Akkaraju sold 96,131 shares of the stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $10.55, for a total transaction of $1,014,182.05. Following the sale, the director directly owned 2,025,493 shares of the company’s stock, valued at approximately $21,368,951.15. This represents a 4.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 33.70% of the company’s stock.

Alumis Profile

Alumis (NASDAQ: ALMS) is a clinical-stage biopharmaceutical company focused on developing oral therapies for immune-mediated diseases. The company’s research is centered on selective modulation of the immune system, with the goal of providing effective, convenient treatments that may address conditions inadequately served by existing therapies.

Its lead product candidate, ESK-001, is an investigational oral allosteric tyrosine kinase 2 (TYK2) inhibitor designed to selectively regulate signaling pathways involved in inflammatory and autoimmune diseases.